Brief: Calliditas Says Nefecon Application Approval In Macau
27/10/2023 08:31
Oct 27 (Reuters) - Calliditas Therapeutics AB
CALTX.ST :
* NEW DRUG APPLICATION APPROVAL BY PHARMACEUTICAL
ADMINISTRATION
BUREAU OF MACAU FOR NEFECON® FOR TREATMENT OF PRIMARY IGA
NEPHROPATHY
* COMMERCIAL PARTNER EVEREST MEDICINES RECEIVED APPROVAL
FROM
PHARMACEUTICAL ADMINISTRATION OF MACAU, CHINA
Source text for Eikon: ID:nWkrbLjGzw
Further company coverage: CALTX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Calliditas Therapeutics AB
See all newsBrief: Calliditas To Be Delisted From Nasdaq Stockholm
Brief: Calliditas Therapeutics Takes Certain Corporate Actions Following Announcement By Asahi Kasei
Brief: Asahi Kasei Corp: Notice Regarding Results Of Tender Offer For Shares Of Calliditas Therapeutics AB And Transfer Of Subsidiary
Calliditas Therapeutics AB reports results for the quarter ended in January - Earnings Summary
Brief: Calliditas Q2 Sales Beat Expectations